Female Health (NASDAQ: VERU) and OMNOVA Solutions (NYSE:OMN) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, profitability, valuation, analyst recommendations, risk, institutional ownership and dividends.
Institutional and Insider Ownership
4.2% of Female Health shares are owned by institutional investors. Comparatively, 89.4% of OMNOVA Solutions shares are owned by institutional investors. 37.0% of Female Health shares are owned by insiders. Comparatively, 4.6% of OMNOVA Solutions shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
This table compares Female Health and OMNOVA Solutions’ net margins, return on equity and return on assets.
||Return on Equity
||Return on Assets
Volatility and Risk
Female Health has a beta of 0.68, meaning that its stock price is 32% less volatile than the S&P 500. Comparatively, OMNOVA Solutions has a beta of 2.07, meaning that its stock price is 107% more volatile than the S&P 500.
Earnings and Valuation
This table compares Female Health and OMNOVA Solutions’ top-line revenue, earnings per share and valuation.
||Earnings Per Share
Female Health has higher earnings, but lower revenue than OMNOVA Solutions. Female Health is trading at a lower price-to-earnings ratio than OMNOVA Solutions, indicating that it is currently the more affordable of the two stocks.
This is a breakdown of recent ratings for Female Health and OMNOVA Solutions, as provided by MarketBeat.
||Strong Buy Ratings
Female Health currently has a consensus price target of $5.00, suggesting a potential upside of 182.49%. OMNOVA Solutions has a consensus price target of $12.00, suggesting a potential upside of 9.59%. Given Female Health’s stronger consensus rating and higher possible upside, equities research analysts plainly believe Female Health is more favorable than OMNOVA Solutions.
OMNOVA Solutions beats Female Health on 8 of the 13 factors compared between the two stocks.
About Female Health
Veru Inc. operates as a urology and oncology biopharmaceutical company. The company operates through two segments, Commercial; and Research and Development. It offers FC2 Female Condom for unintended pregnancy and sexually transmitted infections, including HIV/AIDS and the Zika virus; and PREBOOST benzocaine medicated individual wipes for the prevention of premature ejaculation. The company's urology drug candidates include Tamsulosin delayed release sachet and Tamsulosin XR capsules that are under bioequivalence study for the treatment of benign prostatic hyperplasia; and Solifenacin delayed release granules, which are under bioequivalence study for the treatment of overactive bladder. Its urology drug candidates also comprise Tadalafil-Finasteride combination capsules that are under bioequivalence study for the treatment of men with lower urinary tract symptoms and enlarged prostate; VERU-944, which is in Phase II clinical trial for the treatment of hot flashes in men on prostate cancer hormonal therapies; and VERU-722 that is in Phase II clinical trial for the treatment of male infertility caused by testicular dysfunction. The company's oncology drug candidate is VERU-111, a novel oral alpha and beta tubulin inhibitor, which is under preclinical study for the treatment of metastatic prostate, breast, endometrial, ovarian, and other cancers. It also develops VERU-111/VERU-112, a novel oral agent targeting colchicine binding site that is under preclinical study for the treatment of gout and familial mediterranean fever. Veru Inc. serves agencies, non-government organizations, ministries of health, and other governmental agencies through distributors and retailers primarily in the United States, Brazil, Spain, France, and the United Kingdom. The company was formerly known as The Female Health Company and changed its name to Veru Inc. in July 2017. Veru Inc. was founded in 1896 and is headquartered in Miami, Florida.
About OMNOVA Solutions
OMNOVA Solutions Inc. provides emulsion polymers, specialty chemicals, and engineered surfaces for various commercial, industrial, and residential end uses in the United States, Europe, and Asia. The company operates in two segments, Specialty Solutions and Performance Materials. The Specialty Solutions segment designs, develops, produces, and markets specialty polymers which are used in various applications, such as architectural and industrial coatings; nonwovens used in hygiene products, filtration, and construction; drilling additives for oil and gas drilling, cementing, and fracking; elastomeric modification of plastic casings and hoses used in household, industrial products, and automobiles; tapes and adhesives; sports surfaces; textile finishes; commercial building refurbishment; new construction; residential cabinets; flooring; ceiling tiles; furnishings; manufactured housing; health care patient; common area furniture; and various industrial films applications. This segment primarily sells its products directly to manufacturers. The Performance Chemicals segment produces resins, binders, antioxidants, hollow plastic pigments, coated fabrics, and rubber reinforcing products which are used in tire cord, polymer stabilization, industrial rubber, carpet, paper, and various other applications. This segment distributes its products primarily through a direct sales force and agents to manufacturers of retail store fixtures, cabinets, furniture, seating, health care components, and other products. OMNOVA Solutions Inc. was founded in 1999 and is headquartered in Beachwood, Ohio.
Receive News & Ratings for Female Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Female Health and related companies with MarketBeat.com's FREE daily email newsletter.